Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05789082RecruitingPhase 1/Phase 2
Divarasib for untreated lung cancer with KRAS G12C
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
Duarte, CaliforniaAges 18 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Duarte, CaliforniaAges 18–130 - NCT05804370RecruitingPhase 3
Gleolan to help surgeons find ovarian cancer during surgery
This Phase 3 study tests whether Gleolan (a medicine given before surgery) helps doctors better see ovarian, fallopian tube, or peritoneal cancer during an operation. It may help improve how well surgeons can remove visible tumor tissue during planned surgery.
Phoenix, ArizonaAges 18 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05751512RecruitingPhase 3
Comparing a new treatment for advanced head and neck cancer that has stopped responding to standard care
This study tests a new drug called MRG003 against two other treatments (cetuximab or methotrexate) for people with a type of head and neck cancer that has come back or spread and has not responded to standard treatments. The goal is to see if the new drug can better control the cancer and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05771675RecruitingEarly Phase 1
Simvastatin trial for symptom relief in pancreatitis
This early-phase study tests whether simvastatin can improve patient-reported symptoms in people with recurrent acute or chronic pancreatitis. It’s meant to see if the medicine is tolerable and helps with how you feel day to day.
Los Angeles, CaliforniaAges 18–75 - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Phoenix, ArizonaAges 18 years+ - NCT05723926Recruiting
Carotid implants to help prevent stroke repeat in atrial fibrillation
This trial tests whether placing a carotid implant can reduce the chance of having another stroke in people with atrial fibrillation who are already taking blood thinners. It aims to prevent stroke recurrence while you continue prescribed anticoagulation.
Rockford, IllinoisAges 18 years+ - NCT05710848RecruitingPhase 1/Phase 2
Study drug for repeat bladder tumor surgery patients
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
Mesa, ArizonaAges 18 years+ - NCT05727904RecruitingPhase 3
New immunotherapy for advanced melanoma, with or without lifileucel
This trial studies whether adding lifileucel (a patient-specific immune-cell treatment) to pembrolizumab works better than pembrolizumab alone. It’s for people with untreated advanced melanoma that cannot be removed by surgery.
Birmingham, AlabamaAges 18–70 - NCT04871607RecruitingPhase 2
Yttrium antibody plus chemotherapy for hard-to-treat Hodgkin lymphoma
This trial studies a targeted antibody therapy with yttrium, combined with intensive chemotherapy, for adults whose Hodgkin lymphoma did not respond well or came back. It may help by delivering cancer-killing radiation directly to lymphoma cells and preparing the body for treatment after transplant conditioning.
Duarte, CaliforniaAges 18 years+ - NCT05731726RecruitingPhase 2
New treatment before surgery for locally advanced rectal cancer
This trial tests whether giving serplulimab (an immune medicine) plus CAPEOX chemotherapy and celecoxib before surgery can shrink locally advanced rectal cancer and improve outcomes. It may help by increasing immune attack on the tumor while chemotherapy helps reduce the cancer before the operation.
Hangzhou, ZhejiangAges 18–75 - NCT05716893RecruitingPhase 2
Aerobic exercise program for people getting breast cancer treatment
This Phase 2 study tests whether a supervised aerobic (cardio) training program can improve health and exercise capacity for people receiving treatment for primary breast cancer. You may join if you currently do very little moderate-to-vigorous exercise and can safely complete a special treadmill test that measures breathing and heart response.
Basking Ridge, New JerseyAges 18 years+ - NCT05739825Recruiting
Fecal transplant to change gut bacteria in C. difficile infection
This trial studies whether fecal microbiota transplantation (a procedure that transfers healthy stool bacteria) can change a person’s gut bacteria after repeated C. difficile infection. It may help reduce recurring infections by restoring a healthier balance of gut microbes.
RomaAges 18–90 - NCT05716516RecruitingPhase 2
Estradiol pill for ER-positive advanced breast cancer
This trial studies whether an estradiol (a form of estrogen) treatment can help people with ER-positive advanced breast cancer. It is mainly for post-menopausal women whose cancer is not curable and has already been treated with endocrine (hormone) therapies.
Lebanon, New HampshireAges 18 years+ - NCT04761328Recruiting
Study fear of cancer coming back and stopping immunotherapy
This study looks at fear of cancer coming back and how people feel about stopping immunotherapy (cancer treatment that helps the immune system). You may be able to join if you’re an adult with a cancer history that included immunotherapy, and if you can safely participate.
Pittsburgh, PennsylvaniaAges 21 years+ - NCT05701306RecruitingPhase 1/Phase 2
Study of APG-115 alone or with APG-2575 for certain childhood and adult cancers
This study tests two experimental drugs for people with neuroblastoma or other solid tumors that have not responded to standard treatment. APG-115 is given alone or with APG-2575 to see if it can shrink tumors and help patients feel better.
Guangzhou, GuangdongAges 5 years+ - NCT05688605RecruitingPhase 1/Phase 2
Study of MRG003 for EGFR-positive advanced cancers
This trial tests a drug called MRG003 for people with certain advanced cancers that have a specific protein, EGFR. The drug targets the cancer cells that have this protein, which may help stop the cancer from growing.
Guangzhou, GuangdongAges 18–75 - NCT05681780RecruitingPhase 1
CD40L-treated immune cells for advanced lung cancer with certain gene changes
This Phase 1 study tests a lab-made immune cell treatment (TIL) boosted with CD40L, plus nivolumab, for stage IV or returning non-small cell lung cancer with specific gene changes (EGFR, ALK, ROS1, or HER2). It aims to help your immune system attack the cancer after it has grown despite standard treatments.
Tampa, FloridaAges 18 years+ - NCT05646862RecruitingPhase 3
Comparing two treatments for advanced breast cancer with a PIK3CA mutation
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
Greenbrae, CaliforniaAges 18 years+ - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Bullhead City, ArizonaAges 18 years+ - NCT05665504Recruiting
Biomarker test for managing early lung nodules after treatment
This study looks at lung “biomarkers” (test results from your nodule/tissue) to better predict risk of cancer coming back and to guide long-term follow-up. It may help doctors choose the best surveillance plan after surgery or other treatment for early, potentially curable lung cancer.
Tampa, FloridaAges 18 years+ - NCT05650619Recruiting
Study of return of kidney disease after transplant
This observational study looks at people with FSGS or minimal change disease whose kidney disease came back after a transplant. The goal is to better understand patterns of recurrence and what factors may be linked to it.
Ann Arbor, MichiganAges Any age - NCT05630794RecruitingPhase 1
Safety study of ONC201 for preventing colon polyps
This trial tests a drug called ONC201 to see if it can safely help prevent colon polyps from coming back in people at high risk. You will take the drug for about 12 weeks and have a second colonoscopy to check results.
Ann Arbor, MichiganAges 18 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,322 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.